Collects health records of people with rare anemia disorders across Europe
Gathers existing medical record data from people with rare anemia disorders.
Plain-language title generated from the registry record
Registry title: RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people of any age with a rare anaemia disorder, such as sickle cell disease or thalassaemia, who give written consent to join a registry.
- Age
- 0 to 100 years
- Sex
- Women and men can join.
- Disease stage
- Diagnosed with a rare anaemia disorder (RAD) by the ORPHANET classification, such as sickle cell disease, thalassaemia, or pyruvate kinase deficiency.
Main reasons for not taking part
- The person or the legal representative of a minor cannot or will not give consent.
- Having only sickle cell or thalassaemia trait (alpha- or beta-thalassaemia trait).
- Having only a trait condition of another recessive rare anaemia disorder.
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 100 years old?
Source: NCT06213402, who can take part
Where in Spain
- Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH)Barcelona, SpainContact: María del Mar Mañú Pereira, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT06213402
- Record updated
- 19 January 2024
- Original description
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise.Read full original descriptionShow less
A Retrospective/Prospective, Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs) With Clinical Significance.
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise.
Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.
Inclusion: Patients must meet all of the following criteria to be included in the RADeep Registry; Age from 0-100, both female and male; Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANET classification); Able and willing to provide written informed consent (patient or legal representative for minors).
Exclusion: Patients diagnosed with SCD or THAL (alpha-thalassaemia and beta-thalassaemia) traits or trait conditions for other recessive RADs; Patient or legal representative for minors unwilling or unable to give consent.